|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8122 USD | +8.84% |
|
+6.83% | -41.14% |
| 05-30 | Coherus Completes Strategic Transformation To Coherus Oncology | RE |
| 05-30 | Coherus BioSciences, Inc., Q1 2025 Earnings Call, May 12, 2025 |
| Capitalization | 94.16M 80.42M 75.06M 69.42M 129M 8.08B 144M 899M 341M 3.77B 353M 346M 13.82B | P/E ratio 2025 * |
-1.11x | P/E ratio 2026 * | -1x |
|---|---|---|---|---|---|
| Enterprise value | -11.79M -10.07M -9.4M -8.69M -16.13M -1.01B -18.07M -113M -42.73M -472M -44.2M -43.29M -1.73B | EV / Sales 2025 * |
-0.2x | EV / Sales 2026 * | 0.41x |
| Free-Float |
95.98% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Coherus Oncology, Inc.
More recommendations
More press releases
More news
| 1 day | +8.84% | ||
| 1 week | +6.83% | ||
| Current month | +11.06% | ||
| 1 month | -2.14% | ||
| 3 months | +5.30% | ||
| 6 months | -46.21% | ||
| Current year | -41.14% |
| 1 week | 0.73 |  | 0.82 |
| 1 month | 0.71 | | 0.87 |
| Current year | 0.71 | | 1.77 |
| 1 year | 0.66 | | 2.43 |
| 3 years | 0.66 | | 14.11 |
| 5 years | 0.66 | | 22.22 |
| 10 years | 0.66 | | 38.1 |
| Manager | Title | Age | Since |
|---|---|---|---|
Denny Lanfear
CEO | Chief Executive Officer | 69 | 01/09/2010 |
Bryan Mcmichael
DFI | Director of Finance/CFO | 47 | 08/12/2023 |
Rosh Dias
CTO | Chief Tech/Sci/R&D Officer | - | 15/03/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Mats Wahlström
BRD | Director/Board Member | 70 | 01/01/2012 |
Denny Lanfear
CHM | Chairman | 69 | 01/09/2010 |
Ali Satvat
BRD | Director/Board Member | 47 | 01/05/2014 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +8.84% | +6.83% | -36.05% | -91.17% | 94.16M | ||
| +0.62% | +0.23% | -15.29% | +135.32% | 698B | ||
| +0.33% | -0.08% | +7.09% | -12.61% | 375B | ||
| +1.14% | -0.12% | +13.96% | +24.15% | 335B | ||
| -1.61% | +0.98% | -55.04% | +10.80% | 313B | ||
| -0.06% | -1.30% | +5.58% | -20.07% | 259B | ||
| -0.54% | -0.68% | +0.01% | +17.48% | 240B | ||
| -0.35% | -1.02% | -14.51% | -6.77% | 217B | ||
| +0.58% | -0.54% | -35.31% | -12.30% | 204B | ||
| +1.38% | +2.23% | -4.64% | +19.53% | 160B | ||
| Average | +0.99% | +1.19% | -13.42% | +6.44% | 280.25B | |
| Weighted average by Cap. | +0.28% | +0.40% | -10.79% | +35.45% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 57.85M 49.41M 46.12M 42.65M 79.16M 4.96B 88.68M 553M 210M 2.32B 217M 212M 8.49B | 95.17M 81.29M 75.87M 70.17M 130M 8.17B 146M 909M 345M 3.81B 357M 350M 13.97B |
| Net income | -160M -137M -128M -118M -219M -13.75B -246M -1.53B -581M -6.41B -601M -589M -23.52B | -99.85M -85.29M -79.6M -73.62M -137M -8.57B -153M -954M -362M -4B -375M -367M -14.66B |
| Net Debt | -106M -90.49M -84.46M -78.11M -145M -9.09B -162M -1.01B -384M -4.24B -397M -389M -15.55B | -55.32M -47.25M -44.1M -40.78M -75.69M -4.75B -84.79M -528M -201M -2.21B -207M -203M -8.12B |
More financial data
* Estimated data
Employees
221
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 08/07/25 | 0.8122 $ | +8.84% | 1,331,782 |
| 07/07/25 | 0.7462 $ | -7.88% | 1,425,217 |
| 03/07/25 | 0.8100 $ | +1.87% | 679,404 |
| 02/07/25 | 0.7951 $ | +4.58% | 1,273,813 |
| 01/07/25 | 0.7603 $ | +3.97% | 1,355,171 |
Delayed Quote Nasdaq, July 09, 2025 at 04:00 am
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
0.8122USD
Average target price
4.683USD
Spread / Average Target
+476.62%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- CHRS Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition